Arkolith/Insider Trading/RARE/Form 4

Kakkis Emil D

President & CEO, DirectorUltragenyx Pharmaceutical Inc. (RARE) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.2M
Net Open-Market Flow
-$1.2M
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Sell(S)54K$22.80$1.2M659K
Mar 1, 2026Grant(A)71K—$0713K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-089278) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML